SLC5A2 and COVID-19: A network meta-analysis comprising 31 studies with nearly 3.7 million participants diagnosed with type 2 diabetes indicated that the incidence of adverse outcomes related to COVID-19 was the least frequent among those given SGLT-2 inhibitors, exhibiting a probability of 6% prior to their diagnosis of COVID-19.